MedPath

Assessment of PENG Block as a Part of Multimodal Analgesia Following Hip Surgeries.

Not Applicable
Active, not recruiting
Conditions
Anesthesia
Interventions
Drug: Pericapsular nerve group (PENG) block
Other: Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.
Registration Number
NCT06916000
Lead Sponsor
Ain Shams University
Brief Summary

to study the effect of Pericapsular nerve group (PENG) block as a part of multimodal analgesia regimen for hip arthroplasties

Detailed Description

PENG block is a novel block described by Giron-Arango in 2018 to anesthesize the anterior hip capsule as it is supplied by branches from femoral, obturator and accessory obturator nerves, sparing motor function is an additional significance So currently the block is used to reduce post operative opioid consumption, delay time rescue analgesia, facilitate positioning for spinal anesthesia for hip surgeries and to accelerate mobility and so hospital discharge saving this vulnerable group of patient from any hospital acquired pneumonia, decreasing hospital stays, and improving recovery times would provide valuable insights into its cost-effectiveness and long-term benefits for healthcare system Our primary outcome to be studied is pain assessment via Numer Rating Scale over 24 hours postoperatively, in addition to to secondary outcomes including the aforementioned advantages.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PENG block group (25 particiants)Pericapsular nerve group (PENG) blockFor postoperative pain management, all patients of this arm will receive 20 ml of 0.25% bupivcacaine according to the technique described by Giron-Arango. In addition, multimodal analgesia will be given including IV paracetamol 1000 mg BID and oral celecoxib tablet 100 mg BID. Also if needed nalbuphine 5 mg IV will be given as demand dose and when the NRS pain score was equal to or greater than 4 points.
Group C: control group (25 participants)Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.Patients will receive only other multimodal analgesics
Primary Outcome Measures
NameTimeMethod
Pain score: pain assessment using a Numeric Rating System (NRS) immediately in the postoperative period.24 hours

Pain score: pain intensity will be evaluated using a Numeric Rating System (NRS) immediately in the postoperative period, every 2 hours during the first 6 hours and then every 6 hours till 24 hours postoperatively. Scores ranging from 0 to 10, with 0 indicating the absence of pain and 10 indicating the worst possible pain.

Secondary Outcome Measures
NameTimeMethod
Rescue analgesia timing and opioid consumption over 24 hours24 hours

Time to first opioid demand and total opioid consumed by each patient individually over 24 hours.

Trial Locations

Locations (1)

Faculty of medicine, Ain Shams University

🇪🇬

Abbasia, Cairo, Egypt

Faculty of medicine, Ain Shams University
🇪🇬Abbasia, Cairo, Egypt

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.